DE69427997T2 - Hybrider mensch/tier faktor viii - Google Patents

Hybrider mensch/tier faktor viii

Info

Publication number
DE69427997T2
DE69427997T2 DE69427997T DE69427997T DE69427997T2 DE 69427997 T2 DE69427997 T2 DE 69427997T2 DE 69427997 T DE69427997 T DE 69427997T DE 69427997 T DE69427997 T DE 69427997T DE 69427997 T2 DE69427997 T2 DE 69427997T2
Authority
DE
Germany
Prior art keywords
human
factor viii
animal
subunits
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69427997T
Other languages
English (en)
Other versions
DE69427997D1 (de
Inventor
John S Lollar
Marschall S Runge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of DE69427997D1 publication Critical patent/DE69427997D1/de
Application granted granted Critical
Publication of DE69427997T2 publication Critical patent/DE69427997T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69427997T 1994-03-11 1994-11-15 Hybrider mensch/tier faktor viii Expired - Fee Related DE69427997T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/212,133 US5663060A (en) 1992-04-07 1994-03-11 Hybrid human/animal factor VIII
PCT/US1994/013200 WO1995024427A1 (en) 1994-03-11 1994-11-15 Hybrid human/animal factor viii

Publications (2)

Publication Number Publication Date
DE69427997D1 DE69427997D1 (de) 2001-09-20
DE69427997T2 true DE69427997T2 (de) 2002-04-04

Family

ID=22789694

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69427997T Expired - Fee Related DE69427997T2 (de) 1994-03-11 1994-11-15 Hybrider mensch/tier faktor viii

Country Status (11)

Country Link
US (1) US5663060A (de)
EP (1) EP0749444B1 (de)
JP (1) JP3406607B2 (de)
AT (1) ATE204298T1 (de)
AU (1) AU693837B2 (de)
CA (1) CA2185327A1 (de)
DE (1) DE69427997T2 (de)
DK (1) DK0749444T3 (de)
ES (1) ES2161278T3 (de)
PT (1) PT749444E (de)
WO (1) WO1995024427A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
AT403438B (de) * 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6340740B1 (en) * 1997-08-26 2002-01-22 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
US6432628B1 (en) 1997-08-26 2002-08-13 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
CA2343916A1 (en) 1998-09-21 2000-03-30 Genetics Institute, Inc. Methods of downmodulating the immune response to therapeutic proteins
JP2002526059A (ja) * 1998-09-23 2002-08-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３１個のヒト分泌タンパク質
EP1144594A1 (de) 1998-11-24 2001-10-17 Regents Of The University Of Minnesota Transgenische zirkulierende endothelzellen
AU2001292861A1 (en) * 2000-09-19 2002-04-02 Emory University Modified factor VIII
EP1351986A2 (de) * 2001-01-12 2003-10-15 The American National Red Cross Verfahren und zusammensetzungen zur verminderung von heparansulfatproteoglykan-vermittelter entfernung von faktor viii
EP1572889B1 (de) 2001-10-05 2008-12-17 Expression Therapeutics, LLC Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
EP1454916A1 (de) * 2002-11-29 2004-09-08 ZLB Behring GmbH Modifizierte cDNA des Factors VIII und Derivate davon
EP1424344A1 (de) * 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte cDNA des Factors VIII und Derivate davon
WO2005046583A2 (en) * 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
WO2006063031A2 (en) * 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
EP3421491A3 (de) 2009-10-30 2019-03-27 Albumedix Ltd Albuminvarianten
EP2498804A4 (de) 2009-11-13 2013-05-08 Puget Sound Blood Ct Faktor-viii-b-zellen-epitopvarianten mit reduzierter immunogenität
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
KR101948337B1 (ko) 2010-11-05 2019-02-14 박스알타 인코퍼레이티드 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체
EP2780364A2 (de) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteine mit verbesserter halbwertzeit und anderen eigenschaften
BR112014018679A2 (pt) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As variantes de albumina
BR112015010318A2 (pt) 2012-11-08 2017-08-22 Albumedix As Variantes de albumina
EP2928303A4 (de) 2012-12-07 2016-07-13 Haplomics Inc Faktor-viii-mutationsreparatur und toleranzinduktion
CN108137674B (zh) 2015-08-20 2022-12-06 阿尔布梅迪克斯医疗有限公司 白蛋白变体和缀合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
EP0218712B1 (de) * 1985-04-12 1992-02-26 Genetics Institute, Inc. Neue prokoagulierungsproteine
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins

Also Published As

Publication number Publication date
DE69427997D1 (de) 2001-09-20
ES2161278T3 (es) 2001-12-01
CA2185327A1 (en) 1995-09-14
EP0749444A1 (de) 1996-12-27
US5663060A (en) 1997-09-02
AU1209695A (en) 1995-09-25
ATE204298T1 (de) 2001-09-15
PT749444E (pt) 2001-11-30
JPH10500282A (ja) 1998-01-13
WO1995024427A1 (en) 1995-09-14
DK0749444T3 (da) 2001-11-26
AU693837B2 (en) 1998-07-09
JP3406607B2 (ja) 2003-05-12
EP0749444B1 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
DE69427997D1 (de) Hybrider mensch/tier faktor viii
CA2133203A1 (en) Hybrid human/porcine factor viii
NO975674D0 (no) Fremgangsmåte for å regulere sialyleringen av proteiner fremstilt av pattedyrceller i kultur
ATE404684T1 (de) Methoden und zusammensetzungen zur transformation von zellen
DE69638314D1 (de) Zirkuläres DNA Molekül mit einem abhängigen Replikationsursprung, seine Herstellungsverfahren und seine Verwendung in der Gentherapie
ATE286126T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
EA200400687A1 (ru) Полицистронная экспрессия антител
ATE257177T1 (de) Adeno-assoziierte virale (avv) liposomen und damit zusammenhängende verfahren
ATE423213T1 (de) Erhöhte expression in pflanzen durch verwendung von nicht-translierter leader-sequenz
TR199903234T2 (xx) Erkek doku tercih edilen d�zenleyici b�lge ve kullan�m�.
DE69637631D1 (de) Künstliche säuger chromosome
DE69632456D1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
DE69932599D1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
DE3751393D1 (de) Pflanzen, resistent gegen den Anti-sens RNS aufweisenden Virus.
PT835137E (pt) Celulas encapsuladas produtoras de particulas virais
DE69932446D1 (de) Verfahren zur herstellung von nukleinsäure- und polypeptidbanken durch in vivo rekombination und ihre verwendungen
Gilliam et al. Illegitimate recombination generates a class switch from C mu to C delta in an IgD-secreting plasmacytoma.
Schwartz Genetic studies on mutant enzymes in maize, V. in vitro interconversion of allelic isozymes
DE69323199T2 (de) Gen für die ataxia-telangiectasia komplementationsgruppe d
AU7093487A (en) Virus resistant plants having coat protein
DE69425809D1 (de) Methoden zur Herstellung von Protein C
ATE109827T1 (de) Verfahren zur herstellung von peptiden, dazu zu verwendendes rekombinantes plasmid und mit diesem plasmid transformierte myelomzellen.
AU1695595A (en) Mammalian thymokine genes
DE69331216D1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
BR8600260A (pt) Processo para a preparacao de triacetoxissilanas a partir de tris(amino)silanas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee